Synchronous Bronchioloalveolar and Squamous Cell Lung Cancer With Different 18F-FDG Avidity on PET/CT

2012 ◽  
Vol 37 (10) ◽  
pp. e255-e256 ◽  
Author(s):  
Thorsten Derlin ◽  
Till Sebastian Clauditz ◽  
Alexander Quaas ◽  
Christian Rolf Habermann
2020 ◽  
Vol 7 (6) ◽  
pp. 520-525
Author(s):  
Fadime Demir ◽  
Ahmet Yanarateş

Objective: This study aimed to investigate the relationship between 18Fluorine-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) parameters and hematological parameters in squamous cell lung cancer without distant metastasis and to investigate the prognostic value of these parameters. Patients and Methods: This study included 155 patients who underwent 18F-FDG PET/CT imaging for squamous cell lung cancer. Metabolic and hematological parameters were analyzed. Metabolic parameters included maximum and mean standardized uptake values (SUVmax and SUVmean), metabolic tumor volume (MTV), total lesional glycolysis (TLG), and maximum tumor-to-blood SUV ratio (SURmax). Hematological parameters included neutrophil, lymphocyte, platelet, neutrophil/lymphocyte count ratio (NLR), and platelet/lymphocyte count ratio (PLR) Results: Overall survival was significantly shorter in patients with TLG > 194, NLR > 3.3, and PLR > 157.2 (p < 0.001, p = 0.001, and p = 0.001, respectively). There was a poor correlation between TLG and NLR (p < 0.001, r = 0.302), TLG and PLR (p < 0.001, r = 0.304). TLG (> 194; hazard ratio 1.704, 95% CI 1.056–2.751, p = 0.027) and Tumor-Node-Metastasis (TNM)-based staging (stage II; hazard ratio 1.965, 95% CI 0.739–5.227, p = 0.019) were independent prognostic factors for overall survival. Conclusion: While PET/CT metabolic parameters had both predictive and independent prognostic values in squamous cell lung cancers, PLR and NLR had only predictive values. It shows that PET/CT metabolic parameters related to the course of the disease are more valuable than hematological parameters in squamous cell lung cancer.


Cells ◽  
2021 ◽  
Vol 10 (2) ◽  
pp. 394
Author(s):  
Nazlisadat Seyed Seyed Khoei ◽  
Robert Carreras-Torres ◽  
Neil Murphy ◽  
Marc J. Gunter ◽  
Paul Brennan ◽  
...  

Bilirubin, an endogenous antioxidant, may play a protective role in cancer development. We applied two-sample Mendelian randomization to investigate whether genetically raised bilirubin levels are causally associated with the risk of ten cancers (pancreas, kidney, endometrium, ovary, breast, prostate, lung, Hodgkin’s lymphoma, melanoma, and neuroblastoma). The number of cases and their matched controls of European descent ranged from 122,977 and 105,974 for breast cancer to 1200 and 6417 for Hodgkin’s lymphoma, respectively. A total of 115 single-nucleotide polymorphisms (SNPs) associated (p < 5 × 10−8) with circulating total bilirubin, extracted from a genome-wide association study in the UK Biobank, were used as instrumental variables. One SNP (rs6431625) in the promoter region of the uridine-diphosphoglucuronate glucuronosyltransferase1A1 (UGT1A1) gene explained 16.9% and the remaining 114 SNPs (non-UGT1A1 SNPs) explained 3.1% of phenotypic variance in circulating bilirubin levels. A one-standarddeviation increment in circulating bilirubin (≈ 4.4 µmol/L), predicted by non-UGT1A1 SNPs, was inversely associated with risk of squamous cell lung cancer and Hodgkin’s lymphoma (odds ratio (OR) 0.85, 95% confidence interval (CI) 0.73–0.99, P 0.04 and OR 0.64, 95% CI 0.42–0.99, p 0.04, respectively), which was confirmed after removing potential pleiotropic SNPs. In contrast, a positive association was observed with the risk of breast cancer after removing potential pleiotropic SNPs (OR 1.12, 95% CI 1.04–1.20, p 0.002). There was little evidence for robust associations with the other seven cancers investigated. Genetically raised bilirubin levels were inversely associated with risk of squamous cell lung cancer as well as Hodgkin’s lymphoma and positively associated with risk of breast cancer. Further studies are required to investigate the utility of bilirubin as a low-cost clinical marker to improve risk prediction for certain cancers.


2008 ◽  
Vol 7 (1) ◽  
pp. 62 ◽  
Author(s):  
Paul P Anglim ◽  
Janice S Galler ◽  
Michael N Koss ◽  
Jeffrey A Hagen ◽  
Sally Turla ◽  
...  

2020 ◽  
Vol 11 (9) ◽  
pp. 2731-2735 ◽  
Author(s):  
Yuriko Ueki ◽  
Manabu Suzuki ◽  
Yuriko Horikawa ◽  
Hiromu Watanabe ◽  
Yoh Yamaguchi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document